Focusing on innovation, unveiling new vision creation.

Link to: News

News

Link to: Projects

Projects

Link to: ESG-Sustainability

ESG

News

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

Qisda Corporation Becomes a Strategic Investor in Sunhawk vision Biotech, Inc.

Qisda Corporation (Stock Symbol: 2352) will subscribe to 4,500,000 privately placed shares of our company at a price of NT$54 per share.

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

The 2024 Nobel Prize in Physiology or Medicine has been awarded for the discovery of microRNA.

本公司「視航生醫(7759)」，正是臺灣首間RNA治療藥物開發技術平台公司，致力研發核酸藥物用於治療近視、乾眼症與其他眼睛疾病，主要核心產品——miRNA-328抑制劑，用於治療近視、乾眼症與眼角膜破損，目前皆進入臨床二期或即將進入臨床三期。

Received authorization from the U.S. FDA to commence a Phase II clinical trial for myopia control in children.

Received authorization from the U.S. FDA to commence a Phase II clinical trial for myopia control in children.

Taiwan FDA approved the Phase-II clinical trial for corneal erosion in Sjogren’s patients.

台灣衛福部食藥署於2022年4月進行第一期臨床試驗GCP查核，查核結果順利，無任何缺失。

Sunhawk’s Drug Shows Promising Results in Phase-II Clinical Trial for Dry Eye Disease.

治療乾眼症核酸新藥，臨床二期試驗解盲成功，患者接受治療之後，乾眼症引起的角膜受損的復原狀況相較於安慰劑組達統計顯著有效意義；患者在自我評估改善程度方面，也遠優於安慰劑組受試者，且安全性良好。

2022 Taipei Biotech Award.

獲得 "2022台北生技獎”

US FDA and Taiwan FDA approved the Phase-I IND in 2021.

台灣衛福部食藥署於2022年4月進行第一期臨床試驗GCP查核，查核結果順利，無任何缺失。

US FDA approved the IND application for phase I clinical trial in 28 days!

狂賀! 美國食品藥物管理局(FDA)無異議並且提前核准執行臨床試驗(IND)

The first study participant was recruited to the phase-2 myopia control trial.

The first study participant was recruited to the phase-2 myopia control trial.

Qisda Corporation Becomes a Strategic Investor in Sunhawk vision Biotech, Inc.

Qisda Corporation (Stock Symbol: 2352) will subscribe to 4,500,000 privately placed shares of our company at a price of NT$54 per share.

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

The 2024 Nobel Prize in Physiology or Medicine has been awarded for the discovery of microRNA.

本公司「視航生醫(7759)」，正是臺灣首間RNA治療藥物開發技術平台公司，致力研發核酸藥物用於治療近視、乾眼症與其他眼睛疾病，主要核心產品——miRNA-328抑制劑，用於治療近視、乾眼症與眼角膜破損，目前皆進入臨床二期或即將進入臨床三期。

Received authorization from the U.S. FDA to commence a Phase II clinical trial for myopia control in children.

Received authorization from the U.S. FDA to commence a Phase II clinical trial for myopia control in children.

Taiwan FDA approved the Phase-II clinical trial for corneal erosion in Sjogren’s patients.

台灣衛福部食藥署於2022年4月進行第一期臨床試驗GCP查核，查核結果順利，無任何缺失。

Sunhawk’s Drug Shows Promising Results in Phase-II Clinical Trial for Dry Eye Disease.

治療乾眼症核酸新藥，臨床二期試驗解盲成功，患者接受治療之後，乾眼症引起的角膜受損的復原狀況相較於安慰劑組達統計顯著有效意義；患者在自我評估改善程度方面，也遠優於安慰劑組受試者，且安全性良好。

2022 Taipei Biotech Award.

獲得 "2022台北生技獎”

US FDA and Taiwan FDA approved the Phase-I IND in 2021.

台灣衛福部食藥署於2022年4月進行第一期臨床試驗GCP查核，查核結果順利，無任何缺失。

US FDA approved the IND application for phase I clinical trial in 28 days!

狂賀! 美國食品藥物管理局(FDA)無異議並且提前核准執行臨床試驗(IND)

最新消息

The 2025 ARVO Annual Meeting Committee accepted our presentation of the Phase-II Trial of anti-microRNA-328 Ophthalmic Solution for Dry Eye Disease.

Read more

2022 Taipei Biotech Award.

Read more

Kaohsiung Office

Taipei Office

© Copyright – Sunhawk Vision Biotech, Inc.

design by Morcept

© Copyright – Sunhawk Vision Biotech, Inc.
design by Morcept